How To Catch The Next Wave Of Cancer Immunotherapy
Forging a development partnership with a big pharma PD-1/L1 sponsor has become a sort of beauty contest with many in the running, and small companies are best advised to invest in good preclinical datasets to make the grade, execs say at the BIO Investor Forum in San Francisco.
You may also be interested in...
Heat Biologics Tightens Belt To Reach Late-2016 Inflection Points
Biotech striving to hold on financially until it can deliver top-line data for bladder and lung cancer immunotherapy candidates, but then it will have to content with Roche entering the bladder cancer market with its PD-L1 inhibitor.
Bristol Likes What It Sees In Five Prime, Invests More In CSF1R Program
Bristol agreed to pay $350m upfront for global rights to Five Prime’s CSF1R antibody program, including FPA008, in a deal that builds on the companies’ previous clinical collaboration agreement.
Bristol Hits Sweet Spot On Checkpoint Inhibitor Combination Pricing
Decision to price combo of Yervoy and Opdivo at just 6% more than Yervoy monotherapy could set a trend for the market.